Precipio (PRPO) Receives a Buy from Maxim Group

In this article:

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Precipio (PRPOResearch Report), with a price target of $7.00. The company’s shares closed last Tuesday at $1.85, close to its 52-week low of $1.72.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.4% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics.

Precipio has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $9.18 and a one-year low of $1.72. Currently, Precipio has an average volume of 397.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products and services include MX-ICP and HemeScreen HRM kits, SmartPath, SmartGen, and ICP liquid biopsy testing. The company was founded in March 1997 and is headquartered in New Haven, CT.

Read More on PRPO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

Latest News Feed